Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Structural Characterization of Receptor-Receptor Interactions in the Allosteric Modulation of G Protein-Coupled Receptor (GPCR) Dimers.

Tytuł:
Structural Characterization of Receptor-Receptor Interactions in the Allosteric Modulation of G Protein-Coupled Receptor (GPCR) Dimers.
Autorzy:
Lazim R; Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea.
Suh D; Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea.
Lee JW; Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea.
Vu TNL; Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea.
Yoon S; Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea.
Choi S; Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Mar 22; Vol. 22 (6). Date of Electronic Publication: 2021 Mar 22.
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Models, Molecular*
Protein Conformation*
Protein Multimerization*
Receptors, G-Protein-Coupled/*chemistry
Receptors, G-Protein-Coupled/*metabolism
Allosteric Regulation ; Animals ; Deep Learning ; Humans ; Ligands ; Machine Learning ; Peptides/chemistry ; Peptides/metabolism ; Protein Binding ; Protein Interaction Domains and Motifs ; Structure-Activity Relationship
References:
Pharmacol Rep. 2018 Oct;70(5):936-950. (PMID: 30103174)
Chem Rev. 2019 Aug 28;119(16):9478-9508. (PMID: 31244000)
Nature. 2014 Jul 31;511(7511):557-62. (PMID: 25042998)
Front Physiol. 2016 Oct 25;7:494. (PMID: 27826255)
Front Endocrinol (Lausanne). 2013 Jan 04;3:175. (PMID: 23316183)
Proteins. 2008 Apr;71(1):215-26. (PMID: 17932932)
Biophys Rep. 2017;3(4):57-63. (PMID: 29238742)
Nat Commun. 2019 Jun 24;10(1):2765. (PMID: 31235691)
BMC Evol Biol. 2009 Mar 27;9:67. (PMID: 19323848)
Curr Top Med Chem. 2018;18(8):714-746. (PMID: 29866008)
Curr Opin Chem Biol. 2001 Jun;5(3):302-7. (PMID: 11479122)
Mol Pharmacol. 2003 Sep;64(3):731-40. (PMID: 12920211)
Science. 2014 Apr 4;344(6179):58-64. (PMID: 24603153)
EMBO J. 2005 Feb 9;24(3):499-509. (PMID: 15660124)
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3684-9. (PMID: 10725388)
Biophys Chem. 2018 Sep;240:63-69. (PMID: 29906639)
Front Endocrinol (Lausanne). 2019 Feb 18;10:53. (PMID: 30833931)
Drug Discov Today. 2018 Feb;23(2):272-285. (PMID: 29097277)
Signal Transduct Target Ther. 2020 Sep 23;5(1):213. (PMID: 32968059)
Sci Signal. 2020 Oct 20;13(654):. (PMID: 33082287)
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11595-9. (PMID: 23798416)
Sci Rep. 2018 Aug 22;8(1):12538. (PMID: 30135446)
J Mol Neurosci. 2010 Jun;41(2):294-303. (PMID: 19960372)
Front Mol Biosci. 2019 May 03;6:29. (PMID: 31131282)
Sci Signal. 2012 Aug 14;5(237):ra59. (PMID: 22894836)
J Chem Inf Model. 2013 Mar 25;53(3):717-25. (PMID: 23413988)
Mol Pharmacol. 2009 Nov;76(5):992-7. (PMID: 19666700)
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15480-5. (PMID: 21896740)
Elife. 2017 Jun 29;6:. (PMID: 28661401)
Nature. 2020 Aug;584(7820):310-314. (PMID: 32580208)
J Biol Chem. 2007 Apr 20;282(16):12154-63. (PMID: 17310064)
Neuron. 2016 Oct 5;92(1):143-159. (PMID: 27641494)
Bioinformatics. 2007 Dec 15;23(24):3386-7. (PMID: 17895276)
Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20352-7. (PMID: 21048085)
Annu Rev Pharmacol Toxicol. 2002;42:409-35. (PMID: 11807178)
Nat Chem Biol. 2014 Sep;10(9):716-22. (PMID: 25038791)
Cell Biochem Biophys. 2018 Jun;76(1-2):29-37. (PMID: 29116599)
J Biol Chem. 2019 Nov 8;294(45):16587-16603. (PMID: 31467080)
Br J Pharmacol. 2018 Nov;175(21):4060-4071. (PMID: 29394497)
EMBO J. 2001 May 1;20(9):2152-9. (PMID: 11331581)
Nature. 2020 Aug;584(7820):304-309. (PMID: 32581365)
J Am Chem Soc. 2011 Sep 14;133(36):14220-3. (PMID: 21846146)
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5772-7. (PMID: 12730379)
Cell Res. 2020 Jul;30(7):564-573. (PMID: 32494023)
Trends Pharmacol Sci. 2016 Dec;37(12):1055-1069. (PMID: 27726881)
J Biol Chem. 2000 Jun 30;275(26):19955-63. (PMID: 10764812)
Neuropharmacology. 2021 Jun 1;190:108426. (PMID: 33279506)
J Neurosci. 2002 Sep 1;22(17):7352-61. (PMID: 12196556)
BMC Bioinformatics. 2018 Oct 1;19(1):345. (PMID: 30285606)
Chem Commun (Camb). 2020 Feb 4;56(10):1573-1576. (PMID: 31930273)
Nature. 2020 Aug;584(7820):298-303. (PMID: 32555460)
Neuropharmacology. 2021 Mar 15;186:108465. (PMID: 33485945)
Mol Cell Endocrinol. 2019 Apr 15;486:89-95. (PMID: 30849406)
Elife. 2017 Aug 10;6:. (PMID: 28829739)
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W285-9. (PMID: 24829450)
J Biomed Sci. 2016 Sep 29;23(1):66. (PMID: 27680328)
J Biol Chem. 2005 Jul 1;280(26):24380-5. (PMID: 15863499)
J Med Chem. 2018 Feb 22;61(4):1382-1414. (PMID: 28737935)
Sci Signal. 2016 Jan 12;9(410):ra5. (PMID: 26758213)
Curr Opin Pharmacol. 2017 Feb;32:96-110. (PMID: 28288370)
Int J Mol Sci. 2019 May 14;20(10):. (PMID: 31091705)
Cell Rep. 2020 May 5;31(5):107605. (PMID: 32375054)
BMC Bioinformatics. 2017 Nov 15;18(1):485. (PMID: 29141584)
Methods Enzymol. 2013;523:61-85. (PMID: 23422426)
J Biol Chem. 2004 Jul 9;279(28):29085-91. (PMID: 15126507)
Biochem Biophys Res Commun. 2015 Jul 31;463(3):180-6. (PMID: 25957476)
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W310-4. (PMID: 16845016)
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11940-5. (PMID: 12189203)
Biochem Biophys Res Commun. 1975 Jun 16;64(4):1160-8. (PMID: 1137592)
Sci Rep. 2017 Dec 4;7(1):16873. (PMID: 29203889)
Nat Med. 2010 Dec;16(12):1393-5. (PMID: 21113156)
J Comput Aided Mol Des. 2016 Jun;30(6):489-512. (PMID: 27349423)
Genome Biol. 2012 Aug 31;13(8):R76. (PMID: 22937800)
Molecules. 2018 Oct 04;23(10):. (PMID: 30287797)
Trends Mol Med. 2019 Oct;25(10):915-929. (PMID: 31377146)
Int J Mol Sci. 2020 Sep 01;21(17):. (PMID: 32882859)
Sci Rep. 2018 Jul 10;8(1):10414. (PMID: 29991736)
Annu Rev Pharmacol Toxicol. 2007;47:1-51. (PMID: 17009927)
J Mol Biol. 2020 Jul 24;432(16):4596-4611. (PMID: 32553728)
Curr Opin Struct Biol. 2019 Apr;55:178-184. (PMID: 31170578)
Nature. 2008 Mar 6;452(7183):93-7. (PMID: 18297054)
Front Mol Neurosci. 2019 Nov 12;12:273. (PMID: 31798411)
J Clin Invest. 2020 Mar 2;130(3):1168-1184. (PMID: 32039920)
Chem Soc Rev. 2015 Jan 7;44(1):91-102. (PMID: 25199043)
Psychopharmacology (Berl). 2018 Nov;235(11):3149-3165. (PMID: 30209534)
Curr Opin Cell Biol. 2019 Apr;57:40-47. (PMID: 30453145)
Neuropharmacology. 2018 Jul 1;136(Pt A):92-101. (PMID: 29305121)
J Comput Chem. 2007 Feb;28(3):644-54. (PMID: 17195156)
Front Endocrinol (Lausanne). 2018 Dec 13;9:760. (PMID: 30619090)
Cell Chem Biol. 2017 Mar 16;24(3):360-370. (PMID: 28286129)
J Phys Chem B. 2018 May 31;122(21):5389-5399. (PMID: 29401388)
PLoS Comput Biol. 2012;8(4):e1002473. (PMID: 22532793)
PLoS Comput Biol. 2012;8(8):e1002649. (PMID: 22916005)
J Comput Aided Mol Des. 2019 Sep;33(9):787-797. (PMID: 31542869)
Angew Chem Int Ed Engl. 2015 Jul 27;54(31):8896-927. (PMID: 26119925)
J Comput Chem. 2019 Apr 30;40(11):1233-1242. (PMID: 30768790)
Curr Opin Struct Biol. 2019 Apr;55:147-153. (PMID: 31102980)
Trends Biochem Sci. 2020 Dec;45(12):1049-1064. (PMID: 32861513)
Annu Rev Biochem. 2019 Jun 20;88:85-111. (PMID: 30901263)
Nucleic Acids Res. 2016 Jul 8;44(W1):W522-8. (PMID: 27131789)
Nature. 2016 Dec 1;540(7631):60-68. (PMID: 27905440)
PLoS One. 2012;7(8):e42023. (PMID: 22870276)
ACS Chem Biol. 2019 Oct 18;14(10):2252-2263. (PMID: 31525028)
Biomed Rep. 2016 May;4(5):528-534. (PMID: 27123243)
Mol Pharmacol. 2003 Oct;64(4):823-32. (PMID: 14500738)
Front Mol Neurosci. 2019 Sep 25;12:230. (PMID: 31607863)
Nat Protoc. 2017 Feb;12(2):255-278. (PMID: 28079879)
Nat Struct Mol Biol. 2004 Aug;11(8):706-13. (PMID: 15235591)
J Recept Signal Transduct Res. 2010 Oct;30(5):272-83. (PMID: 20684666)
J Chem Inf Model. 2020 Apr 27;60(4):2294-2303. (PMID: 32233432)
Neuropsychopharmacology. 2014 Jan;39(1):131-55. (PMID: 24105074)
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2383-2388. (PMID: 29463720)
J Mol Biol. 1998 Jul 3;280(1):1-9. (PMID: 9653027)
Nat Rev Mol Cell Biol. 2015 Feb;16(2):69-81. (PMID: 25589408)
Pharmacol Ther. 2009 Nov;124(2):248-57. (PMID: 19664655)
Nature. 2019 Feb;566(7742):79-84. (PMID: 30675062)
J Neurosci. 2001 Oct 15;21(20):8043-52. (PMID: 11588177)
Nucleic Acids Res. 2016 Jul 8;44(W1):W536-41. (PMID: 27141963)
J Biol Chem. 2007 Nov 9;282(45):33000-8. (PMID: 17855348)
Bioinformatics. 2014 Feb 01;30(3):335-42. (PMID: 24281696)
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):378-83. (PMID: 14691258)
Front Pharmacol. 2019 Feb 19;10:114. (PMID: 30837880)
Proteomics. 2016 Oct;16(20):2698-2705. (PMID: 27392515)
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W363-7. (PMID: 15980490)
Nat Chem Biol. 2020 Sep;16(9):946-954. (PMID: 32541966)
Br J Pharmacol. 2011 Sep;164(2b):521-37. (PMID: 21470207)
Molecules. 2017 Nov 08;22(11):. (PMID: 29117144)
J Am Chem Soc. 2011 Mar 9;133(9):3144-57. (PMID: 21319744)
Grant Information:
NRF-2020R1A2C2101636 Mid-career Researcher Program; 2018R1A5A2025286 Medical Research Center (MRC) grant; NRF-2019M3E5D4065251 Bio & Medical Technology Development Program
Contributed Indexing:
Keywords: G protein-coupled receptor (GPCR); PPI prediction; allosteric modulation; dimerization; peptide design; protein dynamics; receptor–receptor interaction
Substance Nomenclature:
0 (Ligands)
0 (Peptides)
0 (Receptors, G-Protein-Coupled)
Entry Date(s):
Date Created: 20210403 Date Completed: 20210430 Latest Revision: 20230106
Update Code:
20240105
PubMed Central ID:
PMC8005122
DOI:
10.3390/ijms22063241
PMID:
33810175
Czasopismo naukowe
G protein-coupled receptor (GPCR) oligomerization, while contentious, continues to attract the attention of researchers. Numerous experimental investigations have validated the presence of GPCR dimers, and the relevance of dimerization in the effectuation of physiological functions intensifies the attractiveness of this concept as a potential therapeutic target. GPCRs, as a single entity, have been the main source of scrutiny for drug design objectives for multiple diseases such as cancer, inflammation, cardiac, and respiratory diseases. The existence of dimers broadens the research scope of GPCR functions, revealing new signaling pathways that can be targeted for disease pathogenesis that have not previously been reported when GPCRs were only viewed in their monomeric form. This review will highlight several aspects of GPCR dimerization, which include a summary of the structural elucidation of the allosteric modulation of class C GPCR activation offered through recent solutions to the three-dimensional, full-length structures of metabotropic glutamate receptor and γ-aminobutyric acid B receptor as well as the role of dimerization in the modification of GPCR function and allostery. With the growing influence of computational methods in the study of GPCRs, we will also be reviewing recent computational tools that have been utilized to map protein-protein interactions (PPI).

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies